BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1170 related articles for article (PubMed ID: 16201938)

  • 1. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistant pathogen-associated skin and skin-structure infections: antibiotic options.
    Curcio D
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1019-36. PubMed ID: 20818946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical challenges and unmet needs in the management of complicated skin and skin structure, and soft tissue infections.
    Turina M; Cheadle WG
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-23-36. PubMed ID: 23577495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cSSTIs: the role of daptomycin.
    Garau J
    Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer treatment options for skin and soft tissue infections.
    Raghavan M; Linden PK
    Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
    Tsoulas C; Nathwani D
    Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factors.
    Zilberberg MD; Shorr AF; Micek ST; Hoban AP; Pham V; Doherty JA; Ramsey AM; Kollef MH
    Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1203-10. PubMed ID: 19848604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The problem of complicated skin and skin structure infections: the need for new agents.
    Moellering RC
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv3-8. PubMed ID: 21115452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antibiotic agents: problems and prospects.
    Weber DJ; Rutala WA
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.